Skip to main content

Bunker Hill Announces Updates to Election to Issue Shares in Satisfaction of Debenture Interest Payment Obligations & Financing Cooperation Fee

KELLOGG, Idaho and VANCOUVER, British Columbia, Dec. 23, 2024 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp. (“Bunker Hill” or the “Company”) (TSXV:BNKR | OTCQB:BHLL) announces certain updates to its news release dated December 20, 2024 in connection with the Company’s election to issue an aggregate of up to 8,446,194 shares of common stock of the Company (“Common Shares”) in full satisfaction of debenture interest payment obligations and outstanding financing cooperation fees, including: (i) an aggregate of up to 7,392,859 Common Shares (the “Interest Shares”) to certain holders of 7.5% convertible debentures (the “Series 1 Convertible Debentures”) and 10.5% convertible debentures (the “Series 2 Convertible Debentures” and, together with the Series 1 Convertible Debentures, the “Convertible Debentures”) in full satisfaction of the...

Continue reading

DMG Blockchain Solutions Secures New Patent To Further Strengthen its Intellectual Property for Regulatory Compliance

VANCOUVER, British Columbia, Dec. 23, 2024 (GLOBE NEWSWIRE) — DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB: DMGGF) (FRANKFURT: 6AX) (“DMG” or the “Company”), a vertically integrated blockchain and data center technology company, announces the issuance of US Patent No. 12,067,572 for Cryptographic Taint Tracking. This patent, issued by the US Patent and Trademark Office, is a continuation of the previously issued U.S. Patent No. 11,257,089. The original patent laid the foundation for a method to detect and track tainted cryptographic wallets, supporting efforts to combat money laundering and fraud. This new patent builds on the innovative technology behind Blockseer’s wallet risk scoring method, which reinforces DMG’s clean-block mining initiative and its use in mining pools. The patented methods enable...

Continue reading

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

• 630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025; • Upon Potential Positive Phase 3 Data the Company Expects to Submit a New Drug Application (“NDA”) for D-PLEX100 under Fast Track and Breakthrough Therapy Designations, Previously Granted to D-PLEX100 by the FDA; • Proceeds from this Financing and Exercise of Data-Triggered Warrant Expected to Extend Cash Runway Beyond Potential NDA Approval PETACH TIKVA, Israel, Dec. 24, 2024 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that following the independent Data Safety Monitoring Board’s (“DSMB”) review of unblinded efficacy data from the first 430 enrolled patients in the SHIELD II Phase 3 trial...

Continue reading

Blockmate Ventures Announces Closing of Strategic Investment and Incentive Grant

TORONTO, Dec. 23, 2024 (GLOBE NEWSWIRE) — Blockmate Ventures Inc. (TSX.V: MATE) (OTCQB: MATEF) (FSE: 8MH1) (“Blockmate” or the “Company”) is pleased to announce that it has closed its strategic investment (the “Offering”) involving a group of strategic investors led by Antanas Guoga (Tony G) for gross proceeds of $1,400,000. This strategic funding supports Blockmate’s pursuit of industry leadership in blockchain innovation and underscores our commitment to sustainable and transformative technology. In connection with completion of the Offering, the Company has issued 14,000,000 units (each, a “Unit”) at a price of $0.10 per Unit. Each Unit consists of one common share, and one common share purchase warrant exercisable to acquire a further common share at a price of $0.50 until December 23, 2027. All securities issued in connection...

Continue reading

Par Pacific Management to Participate in Investor Conferences

HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) — Par Pacific Holdings, Inc. (NYSE: PARR) (“Par Pacific”) today announced that members of its management team will participate in the following investor conferences.Goldman Sachs Energy, CleanTech & Utilities Conference on January 8, 2025 in Miami, Florida UBS Global Energy & Utilities Winter Conference on January 14, 2025 in Park City, UtahThe most current investor presentation is available on the Investors section of Par Pacific’s website at www.parpacific.com. About Par Pacific Par Pacific Holdings, Inc. (NYSE: PARR), headquartered in Houston, Texas, is a growing energy company providing both renewable and conventional fuels to the western United States. Par Pacific owns and operates 219,000 bpd of combined refining capacity across four locations in Hawaii, the Pacific Northwest and...

Continue reading

Applied Optoelectronics Closes Exchange of 2026 Notes and Concurrent Registered Direct Offering

SUGAR LAND, Texas, Dec. 23, 2024 (GLOBE NEWSWIRE) — Applied Optoelectronics, Inc. (NASDAQ: AAOI) (“AOI,” “we,” “us” or “our”) announced today that it has closed its exchange with holders (the “Noteholders”) of its 5.25% Convertible Senior Notes due 2026 (the “2026 Notes”) of approximately $76.7 million principal amount of the 2026 Notes for (i) $125 million aggregate principal amount of 2.75% Convertible Senior Notes due 2030 (the “2030 Notes”), (ii) 1,487,874 shares of our common stock (the “Exchange Shares”) and (iii) approximately $89.6 thousand in cash representing accrued interest on the 2026 Notes and the value of fractional shares (such transactions, collectively, the “Exchanges”). The 2030 Notes are our senior, unsecured obligations and are equal in right of payment with our existing and future senior, unsecured indebtedness,...

Continue reading

Ashland signs definitive agreement to sell Avoca business to Mane

Wilmington, Del., Dec. 23, 2024 (GLOBE NEWSWIRE) — Ashland Inc. (NYSE: ASH) announced today that it has signed a definitive agreement to sell its Avoca business to Mane. The transaction is expected to close in the calendar first quarter 2025, subject to the satisfaction of customary closing conditions. Ashland’s Avoca business supplies Sclareolide, a fragrance fixative, and a range of contract manufacturing capabilities from two production facilities in North Carolina and Wisconsin.  The Avoca business line represents the last entity from Ashland’s previous acquisition of Pharmachem. “The Avoca business is a strong player in the fragrance fixative space with a dedicated team and attractive manufacturing capabilities to meet customer needs,” said Guillermo Novo, chair and chief executive officer, Ashland. “I want to thank...

Continue reading

Christine Healy’s Start Date as President and CEO of Northland Power Updated to January 20, 2025

TORONTO, Dec. 23, 2024 (GLOBE NEWSWIRE) — Northland Power Inc. (TSX: NPI) (“Northland” or the “Company”) announced today that Christine Healy will officially assume the role of President and Chief Executive Officer and be appointed as a director of the Company on January 20, 2025, following an update to the timelines previously shared at the time of her appointment. “We are thrilled that Christine was able to arrange her affairs to join us earlier than expected. We are looking forward to welcoming her to Northland on January 20, 2025,” said John Brace, Interim President & CEO and Board Chair. ABOUT NORTHLAND POWER Northland Power is a global power producer dedicated to helping the clean energy transition by producing electricity from clean renewable resources. Founded in 1987, Northland has a long history of developing, building,...

Continue reading

Host Hotels & Resorts Announces Fourth Quarter 2024 Earnings Call to be Held on February 20, 2025

BETHESDA, Md., Dec. 23, 2024 (GLOBE NEWSWIRE) — Host Hotels & Resorts, Inc. (NASDAQ: HST) (the “Company”), the nation’s largest lodging real estate investment trust, will report fourth quarter 2024 financial results on Wednesday, February 19, 2025, after the market close. The Company will hold a conference call to discuss its fourth quarter 2024 results and business outlook on Thursday, February 20, 2025, at 10:00 a.m. ET. Conference call access information is as follows: Conference Call:USA/Canada Toll Free Number 888-500-3691International Toll Number 646-307-1951Conference ID 71987   A simultaneous webcast of the call will be available on the Company’s website at www.hosthotels.com. A replay of the call will be available Thursday, February 20, 2025, until Saturday, March 22, 2025, via webcast on the Company’s...

Continue reading

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version of the webcast will be available within 24 hours after the end of the live discussion. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.